- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 120 Pages
Asia Pacific
From €4786EUR$4,950USD£4,111GBP
- Report
- November 2023
- 150 Pages
Global
From €4689EUR$4,850USD£4,028GBP
- Report
- March 2024
- 199 Pages
Global
From €3262EUR$3,374USD£2,802GBP
€3624EUR$3,749USD£3,113GBP
- Report
- February 2024
- 175 Pages
Global
From €4834EUR$5,000USD£4,152GBP
- Report
- February 2024
- 120 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- October 2023
- 145 Pages
Global
From €3045EUR$3,150USD£2,616GBP
- Report
- October 2023
- 85 Pages
United States
From €4592EUR$4,750USD£3,945GBP
- Report
- August 2022
- 111 Pages
Global
From €4592EUR$4,750USD£3,945GBP
- Report
- March 2021
- 52 Pages
Global
€1274EUR$1,318USD£1,094GBP
- Report
- September 2018
- 132 Pages
Global
From €5801EUR$6,000USD£4,983GBP
- Report
- October 2023
- 81 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- February 2024
- 184 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- February 2024
- 182 Pages
Global
From €3480EUR$3,600USD£2,990GBP
- Report
- April 2023
- 147 Pages
Global
From €5800EUR$5,999USD£4,982GBP
Ankylosing Spondylitis (AS) is a chronic, inflammatory disorder of the spine and sacroiliac joints. It is classified as a type of spondyloarthritis, a group of diseases that affect the spine and other joints. AS is an autoimmune disorder, meaning that the body's immune system mistakenly attacks healthy tissue. Symptoms of AS include pain and stiffness in the lower back and hips, fatigue, and reduced mobility. Treatment options include physical therapy, exercise, and medications such as non-steroidal anti-inflammatory drugs (NSAIDs) and biologic drugs.
The Ankylosing Spondylitis market is a subset of the Allergy and Immunology market. It is a growing market, driven by the increasing prevalence of AS and the development of new treatments. The market is highly competitive, with a number of companies offering treatments for AS.
Some companies in the Ankylosing Spondylitis market include AbbVie, Amgen, Pfizer, and UCB. Show Less Read more